1
|
Rodríguez-Arévalo S, Pujol E, Abás S, Galdeano C, Escolano C, Vázquez S. Synthesis, Characterization and HPLC Analysis of the (1 S,2 S,5 R)-Diastereomer and the Enantiomer of the Clinical Candidate AR-15512. Molecules 2021; 26:906. [PMID: 33572112 PMCID: PMC7914790 DOI: 10.3390/molecules26040906] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 01/30/2021] [Accepted: 02/05/2021] [Indexed: 02/07/2023] Open
Abstract
AR-15512 (formerly known as AVX-012 and WS-12) is a TRPM8 receptor agonist currently in phase 2b clinical trials for the treatment of dry eye. This bioactive compound with menthol-like cooling activity has three stereogenic centers, and its final structure and absolute configuration, (1R,2S,5R), have been previously solved by cryo-electron microscopy. The route of synthesis of AR-15512 has also been reported, revealing that epimerization processes at the C-1 can occur at specific stages of the synthesis. In order to confirm that the desired configuration of AR-15512 does not change throughout the process and to discard the presence of the enantiomer in the final product due to possible contamination of the initial starting material, both the enantiomer of AR-15512 and the diastereomer at the C-1 were synthesized and fully characterized. In addition, the absolute configuration of the (1S,2S,5R)-diastereomer was determined by X-ray crystallographic analysis, and new HPLC methods were designed and developed for the identification of the two stereoisomers and their comparison with the clinical candidate AR-15512.
Collapse
Affiliation(s)
- Sergio Rodríguez-Arévalo
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l’Alimentació, Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (S.R.-A.); (E.P.); (S.A.)
| | - Eugènia Pujol
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l’Alimentació, Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (S.R.-A.); (E.P.); (S.A.)
| | - Sònia Abás
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l’Alimentació, Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (S.R.-A.); (E.P.); (S.A.)
| | - Carles Galdeano
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain;
| | - Carmen Escolano
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l’Alimentació, Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (S.R.-A.); (E.P.); (S.A.)
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l’Alimentació, Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (S.R.-A.); (E.P.); (S.A.)
| |
Collapse
|
2
|
Griñán-Ferré C, Codony S, Pujol E, Yang J, Leiva R, Escolano C, Puigoriol-Illamola D, Companys-Alemany J, Corpas R, Sanfeliu C, Pérez B, Loza MI, Brea J, Morisseau C, Hammock BD, Vázquez S, Pallàs M, Galdeano C. Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease. Neurotherapeutics 2020; 17:1825-1835. [PMID: 32488482 PMCID: PMC7851240 DOI: 10.1007/s13311-020-00854-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
The inhibition of the enzyme soluble epoxide hydrolase (sEH) has demonstrated clinical therapeutic effects in several peripheral inflammatory-related diseases, with 3 compounds in clinical trials. However, the role of this enzyme in the neuroinflammation process has been largely neglected. Herein, we disclose the pharmacological validation of sEH as a novel target for the treatment of Alzheimer's disease (AD). Evaluation of cognitive impairment and pathological hallmarks were used in 2 models of age-related cognitive decline and AD using 3 structurally different and potent sEH inhibitors as chemical probes. sEH is upregulated in brains from AD patients. Our findings supported the beneficial effects of central sEH inhibition, regarding reducing cognitive impairment, neuroinflammation, tau hyperphosphorylation pathology, and the number of amyloid plaques. This study suggests that inhibition of inflammation in the brain by targeting sEH is a relevant therapeutic strategy for AD.
Collapse
Affiliation(s)
- Christian Griñán-Ferré
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Eugènia Pujol
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Jun Yang
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, CA, 95616, USA
| | - Rosana Leiva
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Carmen Escolano
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Dolors Puigoriol-Illamola
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Júlia Companys-Alemany
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Rubén Corpas
- Institute of Biomedical Research of Barcelona, Consejo Superior de Investigaciones Científicas and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Rosselló, 149, E-08036, Barcelona, Spain
- Centros de Investigacion Biomedica en red Epidemiology and Public Health, Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0, E-28029, Madrid, Spain
| | - Coral Sanfeliu
- Institute of Biomedical Research of Barcelona, Consejo Superior de Investigaciones Científicas and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Rosselló, 149, E-08036, Barcelona, Spain
- Centros de Investigacion Biomedica en red Epidemiology and Public Health, Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0, E-28029, Madrid, Spain
| | - Belen Pérez
- Department of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, E-08193, Barcelona, Spain
| | - M Isabel Loza
- Innopharma Screening Platform, Biofarma Research Group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas, Universidad de Santiago de Compostela, Edificio CIMUS, Av. Barcelona, S/N, E-15706, Santiago de Compostela, Spain
| | - José Brea
- Innopharma Screening Platform, Biofarma Research Group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas, Universidad de Santiago de Compostela, Edificio CIMUS, Av. Barcelona, S/N, E-15706, Santiago de Compostela, Spain
| | - Christophe Morisseau
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, CA, 95616, USA
| | - Bruce D Hammock
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, CA, 95616, USA
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
| | - Mercè Pallàs
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
| | - Carles Galdeano
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
| |
Collapse
|
3
|
Codony S, Pujol E, Pizarro J, Feixas F, Valverde E, Loza MI, Brea JM, Saez E, Oyarzabal J, Pineda-Lucena A, Pérez B, Pérez C, Rodríguez-Franco MI, Leiva R, Osuna S, Morisseau C, Hammock BD, Vázquez-Carrera M, Vázquez S. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis. J Med Chem 2020; 63:9237-9257. [PMID: 32787085 DOI: 10.1021/acs.jmedchem.0c00310] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
In vivo pharmacological inhibition of soluble epoxide hydrolase (sEH) reduces inflammatory diseases, including acute pancreatitis (AP). Adamantyl ureas are very potent sEH inhibitors, but the lipophilicity and metabolism of the adamantane group compromise their overall usefulness. Herein, we report that the replacement of a methylene unit of the adamantane group by an oxygen atom increases the solubility, permeability, and stability of three series of urea-based sEH inhibitors. Most of these oxa-analogues are nanomolar inhibitors of both the human and murine sEH. Molecular dynamics simulations rationalize the molecular basis for their activity and suggest that the presence of the oxygen atom on the adamantane scaffold results in active site rearrangements to establish a weak hydrogen bond. The 2-oxaadamantane 22, which has a good solubility, microsomal stability, and selectivity for sEH, was selected for further in vitro and in vivo studies in models of cerulein-induced AP. Both in prophylactic and treatment studies, 22 diminished the overexpression of inflammatory and endoplasmic reticulum stress markers induced by cerulein and reduced the pancreatic damage.
Collapse
Affiliation(s)
- Sandra Codony
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| | - Eugènia Pujol
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| | - Javier Pizarro
- Pharmacology, Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, 28029 Madrid, Spain.,Pediatric Research Institute-Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
| | - Ferran Feixas
- CompBioLab Group, Departament de Quı́mica and Institut de Quı́mica Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, 17003 Girona, Spain
| | - Elena Valverde
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| | - M Isabel Loza
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain
| | - José M Brea
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain
| | - Elena Saez
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
| | - Julen Oyarzabal
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
| | - Antonio Pineda-Lucena
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
| | - Belén Pérez
- Department of Pharmacology, Therapeutics and Toxicology, Institute of Neurosciences, Autonomous University of Barcelona, Bellaterra, 08193 Barcelona, Spain
| | - Concepción Pérez
- Institute of Medicinal Chemistry, Spanish National Research Council (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - María Isabel Rodríguez-Franco
- Institute of Medicinal Chemistry, Spanish National Research Council (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - Rosana Leiva
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Universitat de Barcelona, 08028 Barcelona, Spain
| | - Sílvia Osuna
- CompBioLab Group, Departament de Quı́mica and Institut de Quı́mica Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, 17003 Girona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Christophe Morisseau
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, Davis, California 95616, United States
| | - Bruce D Hammock
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, Davis, California 95616, United States
| | - Manuel Vázquez-Carrera
- Pharmacology, Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, 28029 Madrid, Spain.,Pediatric Research Institute-Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
| | - Santiago Vázquez
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| |
Collapse
|
4
|
Pujol E, Puigmarti C, Pelaez S, Garcia S. Radiation dose variables related to the causes of skin toxicities in women with breast cancer: A study proposal. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz276.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Casanovas N, Narro F, Del Castillo P, Guma J, Pujol E, Caresia P, Garcia-Vega D, Valcarcel D, Berna L, Martinez-Rubio A. P135Pharmacologic stress SPECT. Are we properly selecting patients for invasive evaluation? Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez147.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- N Casanovas
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Cardiology, Sabadell, Spain
| | - F Narro
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Cardiology, Sabadell, Spain
| | - P Del Castillo
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Cardiology, Sabadell, Spain
| | - J Guma
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Cardiology, Sabadell, Spain
| | - E Pujol
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Cardiology, Sabadell, Spain
| | - P Caresia
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Nuclear Medicine, Sabadell, Spain
| | - D Garcia-Vega
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Cardiology, Sabadell, Spain
| | - D Valcarcel
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Cardiology, Sabadell, Spain
| | - L Berna
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Nuclear Medicine, Sabadell, Spain
| | - A Martinez-Rubio
- Hospital de Sabadell. Institut Universitari Parc Tauli-UAB, Cardiology, Sabadell, Spain
| |
Collapse
|
6
|
Zarei M, Pujol E, Quesada-López T, Villarroya F, Barroso E, Vázquez S, Pizarro-Delgado J, Palomer X, Vázquez-Carrera M. Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. Br J Pharmacol 2019; 176:2292-2305. [PMID: 30927369 DOI: 10.1111/bph.14678] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Revised: 03/11/2019] [Accepted: 03/11/2019] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND AND PURPOSE FGF21 has emerged as a therapeutic strategy for treating type 2 diabetes mellitus due to its antidiabetic effects, and this has led to the development of long-acting analogues of FGF21. However, these compounds have some limitations, including a need to be administered by s.c. injection and their prolonged pharmacodynamic effect compared with native FGF21, which might be responsible for their reported side effects. EXPERIMENTAL APPROACH We have previously demonstrated that i.p. administration of haem-regulated eukaryotic translation initiation factor 2α kinase (HRI) activators increases hepatic and circulating levels of FGF21. In this study, we examined the effects of p.o. administration of a new HRI activator, EPB-53, on high-fat diet (HFD)-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia, and compared them with those of metformin. KEY RESULTS EPB-53 administration for the last 2 weeks, to mice fed a HFD for 10 weeks, reduced body weight gain, improved glucose intolerance, and prevented hepatic steatosis and hypertriglyceridaemia, whereas metformin only ameliorated glucose intolerance. Moreover, EPB-53, similar to the reported effects of FGF21, reduced lipogenesis in cultured human hepatocytes and in the liver of mice fed a HFD. Administration of EPB-53 to Fgf21-knockout mice had no effects, demonstrating that its efficacy is dependent on this hormone. CONCLUSIONS AND IMPLICATIONS Overall, the findings of this study demonstrate that p.o. administration of HRI activators, by increasing FGF21, is a promising strategy for the treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Collapse
Affiliation(s)
- Mohammad Zarei
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.,Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Eugènia Pujol
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain
| | - Tania Quesada-López
- Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain.,Department of Biochemistry and Molecular Biomedicine, IBUB, University of Barcelona, Barcelona, Spain.,Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Francesc Villarroya
- Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain.,Department of Biochemistry and Molecular Biomedicine, IBUB, University of Barcelona, Barcelona, Spain.,Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Emma Barroso
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.,Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Santiago Vázquez
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain
| | - Javier Pizarro-Delgado
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.,Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Xavier Palomer
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.,Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Manuel Vázquez-Carrera
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.,Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| |
Collapse
|
7
|
Pujol E, Blanco-Cabra N, Julián E, Leiva R, Torrents E, Vázquez S. Pentafluorosulfanyl-containing Triclocarban Analogs with Potent Antimicrobial Activity. Molecules 2018; 23:molecules23112853. [PMID: 30400165 PMCID: PMC6278391 DOI: 10.3390/molecules23112853] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 10/25/2018] [Accepted: 10/26/2018] [Indexed: 01/15/2023] Open
Abstract
Concerns have been raised about the long-term accumulating effects of triclocarban, a polychlorinated diarylurea widely used as an antibacterial soap additive, in the environment and in human beings. Indeed, the Food and Drug Administration has recently banned it from personal care products. Herein, we report the synthesis, antibacterial activity and cytotoxicity of novel N,N′-diarylureas as triclocarban analogs, designed by reducing one or more chlorine atoms of the former and/or replacing them by the novel pentafluorosulfanyl group, a new bioisostere of the trifluoromethyl group, with growing importance in drug discovery. Interestingly, some of these pentafluorosulfanyl-bearing ureas exhibited high potency, broad spectrum of antimicrobial activity against Gram-positive bacterial pathogens, and high selectivity index, while displaying a lower spontaneous mutation frequency than triclocarban. Some lines of evidence suggest a bactericidal mode of action for this family of compounds.
Collapse
Affiliation(s)
- Eugènia Pujol
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
| | - Núria Blanco-Cabra
- Bacterial Infections and Antimicrobial Therapies, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 15-21, 08028 Barcelona, Spain.
| | - Esther Julián
- Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
| | - Rosana Leiva
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
| | - Eduard Torrents
- Bacterial Infections and Antimicrobial Therapies, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 15-21, 08028 Barcelona, Spain.
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
| |
Collapse
|
8
|
Vázquez S, Codony S, Pizarro J, Pujol E, Valverde E, Loza I, Brea JM, Saez E, Oyarzabal J, Vázquez‐Carrera M, Leiva R. Novel Soluble Epoxide Hydrolase Inhibitors Featuring a 2‐Oxaadamantane Moiety: Synthesis,
in vitro
Profiling and
in vivo
Evaluation in Murine Models of Acute Pancreatitis. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.560.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Javier Pizarro
- PharmacologyUniversitat de Barcelona and IBUBBarcelonaSpain
| | - Eugènia Pujol
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Elena Valverde
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Isabel Loza
- Drug Screening Platform/Biofarma Research GroupCIMUS Research Center. University of Santiago de Compostela (USC)Santiago de CompostelaSpain
| | - José M. Brea
- Drug Screening Platform/Biofarma Research GroupCIMUS Research Center. University of Santiago de Compostela (USC)Santiago de CompostelaSpain
| | - Elena Saez
- Small Molecule Discovery Platform, Molecular Therapeutics ProgramCenter for Applied Medical Research (CIMA)University of NavarraPamplonaSpain
| | - Julen Oyarzabal
- Small Molecule Discovery Platform, Molecular Therapeutics ProgramCenter for Applied Medical Research (CIMA)University of NavarraPamplonaSpain
| | | | - Rosana Leiva
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| |
Collapse
|
9
|
Zarei M, Barroso E, Palomer X, Dai J, Rada P, Quesada-López T, Escolà-Gil JC, Cedó L, Zali MR, Molaei M, Dabiri R, Vázquez S, Pujol E, Valverde ÁM, Villarroya F, Liu Y, Wahli W, Vázquez-Carrera M. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. Mol Metab 2017; 8:117-131. [PMID: 29289645 PMCID: PMC5985050 DOI: 10.1016/j.molmet.2017.12.008] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 12/08/2017] [Accepted: 12/13/2017] [Indexed: 12/22/2022] Open
Abstract
Objective The very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis. In this study, we investigated the role of Peroxisome Proliferator-Activated Receptor (PPAR)β/δ and fibroblast growth factor 21 (FGF21) in hepatic VLDLR regulation. Methods Studies were conducted in wild-type and Pparβ/δ-null mice, primary mouse hepatocytes, human Huh-7 hepatocytes, and liver biopsies from control subjects and patients with moderate and severe hepatic steatosis. Results Increased VLDLR levels were observed in liver of Pparβ/δ-null mice and in Pparβ/δ-knocked down mouse primary hepatocytes through mechanisms involving the heme-regulated eukaryotic translation initiation factor 2α (eIF2α) kinase (HRI), activating transcription factor (ATF) 4 and the oxidative stress-induced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways. Moreover, by using a neutralizing antibody against FGF21, Fgf21-null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating endoplasmic reticulum (ER) stress-induced VLDLR upregulation. Finally, in liver biopsies from patients with moderate and severe hepatic steatosis, we observed an increase in VLDLR levels that was accompanied by a reduction in PPARβ/δ mRNA abundance and DNA-binding activity compared with control subjects. Conclusions Overall, these findings provide new mechanisms by which PPARβ/δ and FGF21 regulate VLDLR levels and influence hepatic steatosis development. PPARβ/δ deficiency leads to increased levels of hepatic VLDLR levels. FGF21 protects against hepatic steatosis by attenuating ER stress-induced VLDLR upregulation. Human hepatic steatosis is accompanied by increased levels of VLDLR and reduced expression of PPARβ/δ. PPARβ/δ and FGF21 may influence NAFLD development by regulating VLDLR levels.
Collapse
Affiliation(s)
- Mohammad Zarei
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Barcelona, Spain; Research Institute-Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Emma Barroso
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Barcelona, Spain; Research Institute-Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Xavier Palomer
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Barcelona, Spain; Research Institute-Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - Jianli Dai
- Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China
| | - Patricia Rada
- Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Barcelona, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, Spain
| | - Tania Quesada-López
- Research Institute-Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine and IBUB, University of Barcelona, Barcelona, Spain; Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBEROBN)-Instituto de Salud Carlos III, Spain
| | - Joan Carles Escolà-Gil
- Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Barcelona, Spain; Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain; Departament de Bioquímica i Biología Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Lidia Cedó
- Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Barcelona, Spain; Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain
| | - Mohammad Reza Zali
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mahsa Molaei
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Reza Dabiri
- lnternal Medicine Department, Semnan University of Medical Sciences, Semnan, Iran
| | - Santiago Vázquez
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain
| | - Eugènia Pujol
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain
| | - Ángela M Valverde
- Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Barcelona, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, Spain
| | - Francesc Villarroya
- Research Institute-Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine and IBUB, University of Barcelona, Barcelona, Spain; Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBEROBN)-Instituto de Salud Carlos III, Spain
| | - Yong Liu
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Institute for Advanced Studies, Wuhan University, Wuhan, China
| | - Walter Wahli
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland; Lee Kong Chian School of Medicine, Nanyang Technological University, 308232, Singapore; INRA ToxAlim, UMR1331, Chemin de Tournefeuille, Toulouse Cedex, France
| | - Manuel Vázquez-Carrera
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Barcelona, Spain; Research Institute-Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
| |
Collapse
|
10
|
Abstract
In clinical records many items are handwritten and difficult to read. We examined clinical histories in a representative sample of case notes from a Spanish general hospital. Two independent observers assigned legibility scores, and a third adjudicated in case of disagreement. Defects of legibility such that the whole was unclear were present in 18 (15%) of 117 reports, and were particularly frequent in records from surgical departments. Through poor handwriting, much information in medical records is inaccessible to auditors, to researchers, and to other clinicians involved in the patient's care. If clinicians cannot be persuaded to write legibly, the solution must be an accelerated switch to computer-based systems.
Collapse
|
11
|
Bellmunt J, Kerst J, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera M, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh A, Pujol E, Perez-Gracia J, González Larriba J, Collado R, Los M, Maciá S, De Wit R. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Ann Oncol 2017; 28:1517-1522. [DOI: 10.1093/annonc/mdx186] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Indexed: 12/17/2022] Open
|
12
|
Zarei M, Barroso E, Leiva R, Barniol-Xicota M, Pujol E, Escolano C, Vázquez S, Palomer X, Pardo V, González-Rodríguez Á, Valverde ÁM, Quesada-López T, Villarroya F, Wahli W, Vázquez-Carrera M. Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency. Diabetes 2016; 65:3185-99. [PMID: 27486236 DOI: 10.2337/db16-0155] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Accepted: 07/12/2016] [Indexed: 11/13/2022]
Abstract
Fibroblast growth factor 21 (FGF21), a peptide hormone with pleiotropic effects on carbohydrate and lipid metabolism, is considered a target for the treatment of diabetes. We investigated the role of peroxisome proliferator-activated receptor (PPAR) β/δ deficiency in hepatic FGF21 regulation. Increased Fgf21 expression was observed in the livers of PPARβ/δ-null mice and in mouse primary hepatocytes when this receptor was knocked down by small interfering RNA (siRNA). Increased Fgf21 was associated with enhanced protein levels in the heme-regulated eukaryotic translation initiation factor 2α (eIF2α) kinase (HRI). This increase caused enhanced levels of phosphorylated eIF2α and activating transcription factor (ATF) 4, which is essential for Fgf21-induced expression. siRNA analysis demonstrated that HRI regulates Fgf21 expression in primary hepatocytes. Enhanced Fgf21 expression attenuated tunicamycin-induced endoplasmic reticulum stress, as demonstrated by using a neutralizing antibody against FGF21. Of note, increased Fgf21 expression in mice fed a high-fat diet or hepatocytes exposed to palmitate was accompanied by reduced PPARβ/δ and activation of the HRI-eIF2α-ATF4 pathway. Moreover, pharmacological activation of HRI increased Fgf21 expression and reduced lipid-induced hepatic steatosis and glucose intolerance, but these effects were not observed in Fgf21-null mice. Overall, these findings suggest that HRI is a potential target for regulating hepatic FGF21 levels.
Collapse
Affiliation(s)
- Mohammad Zarei
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Emma Barroso
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Rosana Leiva
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain
| | - Marta Barniol-Xicota
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain
| | - Eugènia Pujol
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain
| | - Carmen Escolano
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain
| | - Santiago Vázquez
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain
| | - Xavier Palomer
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Virginia Pardo
- CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, Spain
| | - Águeda González-Rodríguez
- CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, Spain
| | - Ángela M Valverde
- CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, Spain
| | - Tania Quesada-López
- Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain Department of Biochemistry and Molecular Biology and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain CIBEROBN, Instituto de Salud Carlos III, Madrid, Spain
| | - Francesc Villarroya
- Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain Department of Biochemistry and Molecular Biology and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain CIBEROBN, Instituto de Salud Carlos III, Madrid, Spain
| | - Walter Wahli
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore INRA ToxAlim, UMR1331, Chemin de Tournefeuille, Toulouse Cedex, France
| | - Manuel Vázquez-Carrera
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Institute of Biomedicine of the University of Barcelona, Barcelona, Spain CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain Pediatric Research Institute, Hospital Sant Joan de Déu, Barcelona, Spain
| |
Collapse
|
13
|
Sepúlveda J, Vieitez J, Vazquez S, Rodriguez Sanchez A, Gallego O, Rodríguez L, Andrade J, González F, Pujol E, Gil Gil M. Patient Profile and Therapeutic Management in Glioblastoma (Gbm): a Subgroup Analysis of a Large Prospective Observational Study of the Neuro-Oncology Investigation Spanish Group (Geino). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu330.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Unyó C, Chaler J, Rojas-Martínez M, Pujol E, Müller B, Garreta R, Mañanas MA. A cross-sectional study comparing strength profile of dorsal and palmar flexor muscles of the wrist in epicondylitis and healthy men. Eur J Phys Rehabil Med 2013; 49:507-515. [PMID: 23138675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Strength training has been proposed by several authors to treat Lateral Epicondylitis. However, there is still a lack of information concerning muscle weakness and its relationship to imbalances and fatigability of forearm muscles during dynamic conditions in subjects after epicondylitis recovery. AIM To analyze the relationship between lateral humeral epicondylitis, and forearm muscle strength and fatigue. SETTING Rehabilitation specialized center POPULATION Cross-sectional study in eight former epicondylitis men free of symptoms and actively working at the moment of the evaluation and eight healthy men volunteers. METHODS Isokinetic tests were performed at different velocities in order to assess strength in concentric and eccentric contractions. Additionally, a long-term concentric test was carried out in order to analyze strength during endurance. The following variables were analyzed: Average torque of dorsal and palmar flexors of the wrist and ratio of agonist/antagonist for non-endurance contractions; length of initial and final plateaus and the slope of average torque decay during the endurance test. RESULTS In both groups, average torque produced by palmar flexor muscles was higher than that produced by dorsal flexor muscles. Patients showed higher strength in palmar flexor muscles, whereas dorsal flexor strength was similar for both populations. Palmar flexor vs. dorsal flexor ratio was significantly higher in patients for eccentric contractions. Regarding fatigue, results showed that torque decreased earlier in patients. CONCLUSIONS AND CLINICAL REHABILITATION IMPACT: Both palmar flexor force and palmar/dorsal ratio in eccentric exercise were significantly higher in patients. This finding indicates a muscular imbalance in patients underlying the epicondylitis condition. Additionally, former patients fatigued earlier. Findings indicate that muscle imbalances and fatigability might be related to lateral epicondylitis. This information may be useful in the design and monitoring of programs intended for lateral epicondylitis rehabilitation. More studies are necessary to conclude if these differences are cause or consequence of the epicondylitis.
Collapse
Affiliation(s)
- C Unyó
- Department of Physical Medicine and Rehabilitation, Egarsat- SUMA. Terrassa, Barcelona, Spain -
| | | | | | | | | | | | | |
Collapse
|
15
|
De Castro J, Domine M, Garcia-Bueno J, Saura S, García R, Sereno M, Juan Vidal O, Pujol E, Rubio-Viqueira B, Cobo M. Clinical outcomes for special populations of patients treated with first-line bevacizumab-based therapy in an observational study (AVVA). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
|
17
|
Pujol E, Faulí A, Anglada MT, López A, Pons M, Fàbregas N. [Ultrasound-guided single dose injection of 0.5% levobupivacaine or 0.5% ropivacaine for a popliteal fossa nerve block in unilateral hallux valgus surgery]. ACTA ACUST UNITED AC 2010; 57:288-92. [PMID: 20527343 DOI: 10.1016/s0034-9356(10)70229-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To compare the perioperative analgesic efficacy of 0.5% levobupivacaine and 0.5% ropivacaine injected in a single dose to block the tibial and peroneal nerves for surgery using a posterior (popliteal fossa) approach. MATERIAL AND METHODS Prospective randomized trial in patients undergoing hallux valgus surgery; anesthesia was provided by blocking nerves in the popliteal fossa with either 0.5% levobupivacaine or 0.5% ropivacaine. Variables studied were times until anesthetic block onset and reversal, need for additional sedation or peripheral block anesthetic, course of postoperative pain at 12, 24 and 48 hours and at 7 days, nighttime rest, need for additional analgesia, and patient satisfaction. RESULTS Forty-six patients were enrolled. Times until onset of the sensory and motor blocks were similar in the 2 groups. For 57.1% of the patients, the sensory and motor block lasted 24 hours after surgery, with no between-group differences. The levobupivacaine group had less pain at rest 24 hours after surgery (mean [SD] visual analog scale score of 0.16 [0375] vs. 1.17 [1.88] in the ropivacaine group; P < .05). No patient reported severe pain or required additional analgesics. None were readmitted. More than 80% rested well at night. No between-group differences were observed. CONCLUSIONS The use of a single dose of either levobupivacaine or ropivacaine to provide anesthesia for a popliteal approach to hallux valgus surgery is effective for controlling postoperative pain.
Collapse
Affiliation(s)
- E Pujol
- Unidad de Cirugía Mayor Ambulatoria, Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Clínic de Barcelona, Universitat de Barcelona.
| | | | | | | | | | | |
Collapse
|
18
|
Saenz A, Avellanet M, Hijos E, Chaler J, Garreta R, Pujol E, Sandoval B, Buen C, Farreny A. Knee isokinetic test-retest: a multicentre knee isokinetic test-retest study of a fatigue protocol. Eur J Phys Rehabil Med 2010; 46:81-88. [PMID: 20332731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
AIM The aim of this study was to establish the test-retest reliability of a knee extensor and flexor muscle fatigue protocol using a biodex system 3 isokinetic dynamometer. METHODS Three-outpatient Rehabilitation Departments undertook the study. Fatigue was evaluated in the dominant knee of 90 healthy female volunteers, non-sportswomen, aged between 20 and 40. They performed 40 consecutive concentric knee flexions and extensions, at 120 degrees /s, on a Biodex 3 isokinetic dynamometer. Two evaluations were done over a period of seven days. Analysed variables were: maximal repetition of total work, maximal work repetition number, work to body weight ratio, total work, work during first and last third of the protocol, fatigue ratio, work fatigue. Statistical analysis determined mean values, medians and box-plots. Intraclass Correlation Coefficients (ICC) (confidence interval 95 %), t-test and one-way analysis of variance (ANOVA) evaluated reliability. Difference of means (di), standard error of measurement (SEM) and 95% of interval confidence (IC di) were also calculated (P<0.05). RESULTS All participants completed the study. Reliability data were excellent (ICC>0.75) for total work (0.85), work during first third (0.80) and last third (0.80) in extension, and for total work in flexion. Reliability data were fair to good (ICC 0.4-0.75) for the rest of the variables. Median varied less than 20% in all cases during test-retest. CONCLUSION This knee fatigue protocol is reliable for flexion and extension, above all when using the total work as a variable. The desirability of multicentre studies in rehabilitation and standardisation of protocols is emphasised.
Collapse
Affiliation(s)
- A Saenz
- Rehabilitation Department, Hospital Nostra Sra de Meritxell, Escaldes Engordany, Andorra
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Serrano S, Martinez-Trufero J, Miguelsanz S, Yubero A, Lastra R, Polo E, Lambea J, Seguí M, Pujol E, Isla D. 8520 Preliminary results of a pilot study with a modified induction docetaxel/cisplatin/5-FU (TPF) followed by concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71611-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
20
|
Isla D, Martínez-Trufero J, Morales S, Yubero A, Lambea J, Álvarez I, Polo E, Seguí MA, Pujol E, Pastor P. A pilot study of modified neoadjuvant docetaxel/cisplatin/5-FU (TPF) to concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC): Preliminary results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6039 Background: Sequential treatment with induction CT followed by CT/RT is highly active and under study in ongoing randomized trials. We started a pilot phase II trial to explore the efficacy, toxicity profile and organ preservation of a modified neoadjuvant TPF to concurrent CT/RT in both resectable (R) and unresectable (UR) LAHNC. Methods: One hundred seventy patients(p) with stage III-IV, PS ECOG 0–2, were included to receive 3 cycles of docetaxel 75 mg/m2 iv day(d) 1, cisplatin(P) 75 mg/m2 iv d2 and 5-FU 750 mg/m2 iv continuous infusion d2–5, every 3 weeks with prophylactic ciprofloxacin 500 mg twice daily from d6–15 of each cycle and granulocyte colony-stimulating factor as secondary or primary setting, followed by P 100 mg/m2 iv d1, 22, 43 concomitant with RT (66–70 Gy, conventional fractionation). Neck dissection was planned for p with stage N2–3 after induction CT or salvage surgery for resectable p with persistent disease at the end of treatment. Results: Main p characteristics were: median age 58 years (39–77), male 89%, ECOG 0/1/2 47%/50.6%/2.4%, stage IV 62.7%, larynx/hipopharynx/oral cavity/oropharynx 45%/12%/17.3%/25.7% and R/UR 41.8%/58.2%. Median TPF/P cycles administered were 3/3. Neoadjuvant CT/total treatment overall response rate evaluation (R/UR): 70% (73%/68%)/86% (84%/88%). Neck dissection was performed in 16 p and salvage surgery in 6 p. Organ preservation was achieved in 90.8% of R p. Main G3–4 toxicity during TPF treatment was neutropenia 11.2%, febrile neutropenia 11.2%, mucositis 11.2%, and during CT/RT mucositis 16.5%, neutropenia 16.5%. Median time to progression was 19.5 m(R:15.6, UR:20.3), and median overall survival was not reached (R:not reached, UR:32.8). Conclusions: Preliminary results indicate that modified neoadjuvant TPF followed by CT/RT is an active and well tolerated regimen in LAHNC, with satisfactory organ preservation and survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Isla
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - J. Martínez-Trufero
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - S. Morales
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - A. Yubero
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - J. Lambea
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - I. Álvarez
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - E. Polo
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - M. A. Seguí
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - E. Pujol
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| | - P. Pastor
- Hospital Clínico Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Obispo Polanco, Teruel, Spain; Hospital San Jorge, Huesca, Spain; Hospital Ernest Lluch, Calatayud, Spain; Consorci Hospitalari Parc Tauli, Sabadell, Spain; Hospital General de Soria, Soria, Spain; Hospital Virgen del Rocío, Sevilla, Spain
| |
Collapse
|
21
|
Bernabeu-Wittel M, García Morillo S, Ollero M, Hernández-Quero J, González de la Puente M, Montero Pérez-Barquero M, Díez F, García-Alegría J, Pujol E, Sanromán C, Cuello J. El Plan Estratégico para el desarrollo de la Medicina Interna en Andalucía. Rev Clin Esp 2008; 208:295-301. [DOI: 10.1157/13123189] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
22
|
Cassinello J, Álvarez JV, García-López MJ, Pujol E, Colmenarejo A, De Segovia F, Marcos F, Filipovich E, García Castro I, Arcediano A. Capecitabine plus oxaliplatin (XELOX) followed by capecitabine plus irinotecan (XELIRI) in a sequential schedule in first-line metastatic colorectal cancer (MCRC): a phase II multicenter study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13516 Background: In phase II trials, XELOX and XELIRI were highly active and well tolerated in first-line MCRC. The aim of this study is to explore the efficacy and safety of XELOX followed by XELIRI as first-line treatment in MCRC. Specifically, we wanted to evaluate the impact of sequential scheduling on the dose-limiting neurotoxicity associated with oxaliplatin accumulation. Methods: Eligible patients (pts) had histologically or cytologically confirmed MCRC, ECOG PS ≤ 2 and adequate bone marrow, renal and hepatic function. Prior chemotherapy for MCRC was not allowed. Pts received 4 cycles of XELOX (capecitabine 1000mg/m2 orally bid d1–14 + oxaliplatin 130mg/m2 i.v. d1, q3w) followed by 4 cycles of XELIRI (capecitabine 1000mg/m2 bid d1–14 + irinotecan 240mg/m2 i.v. d1, q3w). This sequential schedule was repeated until unacceptable toxicity or disease progression. Results: Of the 35 pts analized to date: M/F (69%/31%); median age 68 years (range 41–78); ECOG PS 0–1 (94%); surgery (77%) and adjuvant chemotherapy (31%). 240 cycles (median 6, range 1–16) have been administered. 35 pts received XELOX (123 cycles, median 4), and 21 pts received XELIRI (83 cycles, median 4) in the first sequential schedule. In the second sequential schedule 6 pts received XELOX (22 cycles, median 4) and 4 pts received XELIRI (12 cycles, median 3.5). Median relative dose intensity was 88% for XEL, 96% for OX and 92% for IRI. In 27 efficacy evaluable pts, the ORR was 48% (95% CI, 29–67%). Eight pts were not evaluable due to adverse events (n=6), ongoing treatment (n=1) and lost of follow up (n=1). Conclusions: This sequential schedule is active and well tolerated in first-line MCRC. The improvement/recovery of the oxaliplatin-related neurotoxicity during the XELIRI phase is also promising and allows the re-treatment with oxapliplatin in the next sequence without accumulating neurotoxicity. Final results will be presented at the meeting. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Cassinello
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - J. V. Álvarez
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - M. J. García-López
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - E. Pujol
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - A. Colmenarejo
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - F. De Segovia
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - F. Marcos
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - E. Filipovich
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - I. García Castro
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| | - A. Arcediano
- General Hospital, Guadalajara, Spain; Hospital Rodríguez Chamorro, Zamora, Spain; Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain; Hospital Santa Bárbara, Soria, Spain; Hospital Central de la Defensa, Madrid, Spain; Hospital Nuestra Señora del Valle, Madrid, Spain; Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; Hospital Nuestra Señora de Sonsoles, Ávila, Spain
| |
Collapse
|
23
|
Camps C, De Las Peñas R, López-Vivanco G, Garde J, Sanchez J, Viñolas N, García-Gómez R, Barón S, Terrasa J, Pujol E. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer: An analysis of the Spanish Lung Cancer Group pharmacogenomic study of cisplatin and docetaxel combination (PLATAX). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7124 Background: Chemotherapy is the standard treatment for advanced non-small-cell lung cancer, and myelosuppression is a common side-effect. We aimed to assess whether haematological toxic effects could be a biological measure of drug activity and a marker of efficacy. Methods: We analysed data of 493 patients who received chemotherapy (cisplatin and docetaxel) within the pharmacogenomic, open-label, single-arm, multicentric PLATAX trial. Three subgroups of patients were considered: global population, patients who received at least three cycles of chemotherapy, and those who received at least six cycles. Neutropenia was categorised on the basis of worst WHO grade during chemotherapy: absent (grade 0), mild (grade 1–2), or severe (grade 3–4). Relative dose intensity was analysed for both drugs. The primary endpoint was overall survival. Results: Median overall survival was 9 months (8.2–9.7). Median relative dose intensity was 0.97 for cisplatin and docetaxel. 403 patients received at least three cycles of chemotherapy, and 255 received six or more. Neutropenia appeared in 172 patients (30.8%), 72 of them G3–4 (18.6%). Dose intensity was lower in patients who presented any grade of neutropenia versus those without neutropenia in the three analyzed subgroups, for both drugs (p < 0.05). Factors associated with higher risk of death were ECOG 1–2 (HR 1.8, p = 0.00) and female (HR 1.5, p = 0.02). There were no differences in overall survival between patients with G0 vs G1–2 vs G3–4 neutropenia (8.7 vs 11.6 vs 9.6 m, p = 0.41), however the risk of death was lower in patients with ECOG 0, that presented neutropenia (HR: 0.545, IC 95%: 0.31, 0.96; p = 0.034). Conclusions: Neutropenia during chemotherapy may be associated with increased survival of patients with advanced non-small cell lung cancer and ECOG 0. Its absence is not a result of underdosing. Prospective trials are needed to assess whether neutropenia could be a biological measure of drug activity and a marker of efficacy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Camps
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - R. De Las Peñas
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - G. López-Vivanco
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - J. Garde
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - J. Sanchez
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - N. Viñolas
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - R. García-Gómez
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - S. Barón
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - J. Terrasa
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| | - E. Pujol
- Hospital General Universitario, Valencia, Spain; H. Prov. de Castellón, Castellón, Spain; Hospital de Cruces, Bilbao, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Gregorio Marañón, Madrid, Spain; Hospital de Santiago, Santiago, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital General de Soria, Soria, Spain
| |
Collapse
|
24
|
Méndez M, Alfonso PG, Pujol E, González E, Castañon C, Cerezuela P, López-Mateos Y, Cruz JJ. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. Invest New Drugs 2005; 23:243-51. [PMID: 15868381 DOI: 10.1007/s10637-005-6733-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
We evaluated the antitumoral efficacy and safety of CPT-11 125 mg/m2 (weekly 90 min i.v. infusion; days 1, 8 and 15) combined with UFT (oral combination of tegafur and uracil) 200 mg/m2/day plus leucovorin (LV) 45 mg/m2/day (both divided into three separate oral doses every 8 h, days 1-21) every 4 weeks as first-line chemotherapy of metastatic colorectal cancer (CRC). Fifty-three patients > or =18 years old with histologically confirmed diagnosis of advanced CRC and bidimensionally measurable disease were enrolled. Three patients (6%) showed CR and 8 patients (15%) showed PR (ORR = 21% (95% CI, 10-32). Stable disease was reported in 19 patients (36%) [tumor control rate = 57% (95% CI, 43-70)]. The median time to progression and overall survival were 7.9 and 18.2 months, respectively (1-year rate = 74%; 2-years rate = 26%). CPT-11/UFT/LV treatment was well tolerated: the most reported grade 3/4 toxicities were neutropenia (11% of patients) and delayed diarrhea (28% of patients). No significant differences in response rate, survival or toxicity were found between younger (< or =65 years) and older patients (> 65 years). Weekly CPT-11 plus UFT/LV was found effective and safe as first-line chemotherapy for metastatic CRC. The addition of CPT-11 to UFT/LV doubled the response rate compared to the results previously reported with UFT/LV, while myelosuppression remained low.
Collapse
Affiliation(s)
- M Méndez
- Hospital de Móstoles, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Camps C, Alonso G, de las Peñas R, Provencio M, Terrasa J, Lopez-Vivanco G, Artal A, Garcia-Gomez R, Pujol E, Rosell R. P-012 XPD polymorphism in second-line treatment with gemcitabine or innotecan in advanced non-small cell lung cancer (NCSLC) patients. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80506-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Cassinello J, Álvarez JV, García-López MJ, Pujol E, Colmenarejo A, de Segovia F, Marcos F, Filipovich E. Phase II multicenter sequential study of oxaliplatin (O) and capecitabine (C) followed by irinotecan (I) and capecitabine (C) in first line advanced colorectal cancer (CRC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Cassinello
- Gen Hosp, Guadalajara, Spain; Hosp Rodríguez Chamorro, Zamora, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Santa Bárbara, Soria, Spain; Hosp Central de la Defensa, Madrid, Spain; Hosp Nuestra Señora del Valle, Madrid, Spain; Hosp Nuestra Señora del Prado, Talavera de la Reina, Spain; Hosp Nuestra Señora de Sonsoles, Ávila, Spain
| | - J. V. Álvarez
- Gen Hosp, Guadalajara, Spain; Hosp Rodríguez Chamorro, Zamora, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Santa Bárbara, Soria, Spain; Hosp Central de la Defensa, Madrid, Spain; Hosp Nuestra Señora del Valle, Madrid, Spain; Hosp Nuestra Señora del Prado, Talavera de la Reina, Spain; Hosp Nuestra Señora de Sonsoles, Ávila, Spain
| | - M. J. García-López
- Gen Hosp, Guadalajara, Spain; Hosp Rodríguez Chamorro, Zamora, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Santa Bárbara, Soria, Spain; Hosp Central de la Defensa, Madrid, Spain; Hosp Nuestra Señora del Valle, Madrid, Spain; Hosp Nuestra Señora del Prado, Talavera de la Reina, Spain; Hosp Nuestra Señora de Sonsoles, Ávila, Spain
| | - E. Pujol
- Gen Hosp, Guadalajara, Spain; Hosp Rodríguez Chamorro, Zamora, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Santa Bárbara, Soria, Spain; Hosp Central de la Defensa, Madrid, Spain; Hosp Nuestra Señora del Valle, Madrid, Spain; Hosp Nuestra Señora del Prado, Talavera de la Reina, Spain; Hosp Nuestra Señora de Sonsoles, Ávila, Spain
| | - A. Colmenarejo
- Gen Hosp, Guadalajara, Spain; Hosp Rodríguez Chamorro, Zamora, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Santa Bárbara, Soria, Spain; Hosp Central de la Defensa, Madrid, Spain; Hosp Nuestra Señora del Valle, Madrid, Spain; Hosp Nuestra Señora del Prado, Talavera de la Reina, Spain; Hosp Nuestra Señora de Sonsoles, Ávila, Spain
| | - F. de Segovia
- Gen Hosp, Guadalajara, Spain; Hosp Rodríguez Chamorro, Zamora, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Santa Bárbara, Soria, Spain; Hosp Central de la Defensa, Madrid, Spain; Hosp Nuestra Señora del Valle, Madrid, Spain; Hosp Nuestra Señora del Prado, Talavera de la Reina, Spain; Hosp Nuestra Señora de Sonsoles, Ávila, Spain
| | - F. Marcos
- Gen Hosp, Guadalajara, Spain; Hosp Rodríguez Chamorro, Zamora, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Santa Bárbara, Soria, Spain; Hosp Central de la Defensa, Madrid, Spain; Hosp Nuestra Señora del Valle, Madrid, Spain; Hosp Nuestra Señora del Prado, Talavera de la Reina, Spain; Hosp Nuestra Señora de Sonsoles, Ávila, Spain
| | - E. Filipovich
- Gen Hosp, Guadalajara, Spain; Hosp Rodríguez Chamorro, Zamora, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Santa Bárbara, Soria, Spain; Hosp Central de la Defensa, Madrid, Spain; Hosp Nuestra Señora del Valle, Madrid, Spain; Hosp Nuestra Señora del Prado, Talavera de la Reina, Spain; Hosp Nuestra Señora de Sonsoles, Ávila, Spain
| |
Collapse
|
27
|
Camps C, de las Penas R, Alonso G, Provencio M, Terrasa J, Lopez Vivanco G, Artal A, Garcia Gomez R, Pujol E, Sanchez JM. XPD 751 polymorphism customized second-line treatment with gemcitabine (G) or irinotecan (I) in advanced non-small cell lung cancer (NCSLC) patients (p). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Camps
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - R. de las Penas
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - G. Alonso
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - M. Provencio
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - J. Terrasa
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - G. Lopez Vivanco
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - A. Artal
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - R. Garcia Gomez
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - E. Pujol
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| | - J. M. Sanchez
- Hosp Gen Univ de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Juan Canalejo, La Coruna, Spain; Hosp Puerta del Hierro, Madrid, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp de Cruces, Vizcaya, Spain; Hosp Univ Miguel Servet, Zaragoza, Spain; Hosp Gen Univ Gregorio Maranon, Madrid, Spain; Hosp Gen de Soria, Soria, Spain; Inst Catala d’Oncologia, Badalona, Spain
| |
Collapse
|
28
|
de Lope ML, Batalha P, Sosa M, Rodríguez-Gómez FJ, Sánchez-Muñoz A, Pujol E, Aguado JM. Pleural empyema due to Salmonella enteritidis in a non-immunocompromised patient. Eur J Clin Microbiol Infect Dis 2004; 23:792-3. [PMID: 15605186 DOI: 10.1007/s10096-004-1204-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M León de Lope
- Service of Internal Medicine, Hospital Juan Ramón Jiménez, Ronda Norte, s/n, 21005, Huelva Spain
| | | | | | | | | | | | | |
Collapse
|
29
|
Quantin X, Pujol E, Stoebner A, Lafontaine T, Papaix C, Tarlet C, Marty D, Godard P. 229 Intérêt d’une consulatation mobile d’aide au sevrage tabagique. Rev Mal Respir 2004. [DOI: 10.1016/s0761-8425(04)71855-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Pujol E, Rodríguez-Cuenca S, Frontera M, Justo R, Lladó I, Kraemer FB, Gianotti M, Roca P. Gender- and site-related effects on lipolytic capacity of rat white adipose tissue. Cell Mol Life Sci 2003; 60:1982-9. [PMID: 14523558 DOI: 10.1007/s00018-003-3125-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Gender- and site-related differences in the lipolytic capacity, at the different steps of the adrenergic pathway, in gonadal and inguinal white adipose tissue (WAT), were assessed by studying alpha2A-adrenergic receptor (AR), beta3-AR and hormone-sensitive lipase (HSL) protein levels, and by determining the lipolytic response to different agents. Gonadal WAT showed a lower alpha2A/beta3-AR ratio, a greater lipolytic capacity in response to AR agonists, and higher HSL activity and protein levels than inguinal WAT. In female rats, we found greater alpha2A-AR protein levels and alpha2A/beta3-AR ratio compared to their male counterparts, but, on the other hand, a higher lipolytic response to beta-AR agonists and a greater lipolytic capacity at the postreceptor level, including a more activated HSL protein. Thus, the lipolytic capacity was clearly higher in gonadal than in inguinal WAT, at the different steps of the adrenergic pathway studied. Moreover, in both tissues, females showed a greater inhibition of lipolysis via alpha2-AR, which was counteracted by the higher lipolytic capacity at the postreceptor level.
Collapse
Affiliation(s)
- E Pujol
- Grup de metabolisme energètic i nutrició, Departament de Biologia Fonamental i Ciències de la Salut, Universitat de les Illes Balears, Cra. Valldemossa km 7.5, 07122 Palma de Mallorca, Spain
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Vinyoles E, Blancafort X, López-Quiñones C, Arqué M, Brau A, Cerdán N, de la Figuera M, Díaz F, Pujol E. Blood pressure measurement in an ambulatory setting: concordance between physician and patient self-measurement. J Hum Hypertens 2003; 17:45-50. [PMID: 12571616 DOI: 10.1038/sj.jhh.1001505] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The aim of this study was to determine concordance between physician and patient blood pressure (BP) measurements in an ambulatory setting. A diagnostic intervention cross-sectional study using a convenience sample was employed. A total of 106 hypertensive patients were included in the study. Patients who were unable to perform their self-measurement or those with cardiac arrhythmia were excluded. BP was determined nine times in each subject in the medical office in a randomised order: BP was taken three times by the physician using a mercury sphygmomanometer (SPH-Hg), three times by the physician using a validated, automated oscillometer (Omron HEM 705 CP), and three times by the patient himself with the same device. The intraclass correlation coefficient was calculated. In all, 59 women and 47 men aged 65.7 (10) years were analysed. Mean BP measurements for the physician using the mercury sphygmomanometer, the physician using the Omron, and the patient using the same device were: 136 (15.8)/80 (11), 137 (17.9)/80 (10), and 139* (17.6)/80 (10) mmHg, respectively. BP control was 48.1, 48.1, and 36.8*% (*P < 0.05), respectively. Intraclass correlation coefficients for systolic/diastolic pressures were: 0.77/0.65 (physician-sphygmomanometer Hg, physician-Omron; P < 0.001), 0.75/0.64 (physician-sphygmomanometer Hg, patient-Omron, P < 0.001), and 0.83/0.83 (physician-Omron, patient-Omron; P < 0.001). In conclusion, the three types of measurement in the medical office were significantly concordant. Patient office self-measurement showed a tendency to increase systolic BP and worsen BP control.
Collapse
Affiliation(s)
- E Vinyoles
- La Mina Primary Care Centre, Family and Community Medicine Teaching Unit, Barcelona, Catalonia, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
In clinical records many items are handwritten and difficult to read. We examined clinical histories in a representative sample of case notes from a Spanish general hospital. Two independent observers assigned legibility scores, and a third adjudicated in case of disagreement. Defects of legibility such that the whole was unclear were present in 18 (15%) of 117 reports, and were particularly frequent in records from surgical departments. Through poor handwriting, much information in medical records is inaccessible to auditors, to researchers, and to other clinicians involved in the patient's care. If clinicians cannot be persuaded to write legibly, the solution must be an accelerated switch to computer-based systems.
Collapse
Affiliation(s)
| | - Y Marín
- Internal Medicine Department, Hospital Juan Ramón Jiménez
de Huelva, Huelva, Spain
| | - A Sánchez
- Internal Medicine Department, Hospital Juan Ramón Jiménez
de Huelva, Huelva, Spain
| | - C Borrachero
- Internal Medicine Department, Hospital Juan Ramón Jiménez
de Huelva, Huelva, Spain
| | - E Pujol
- Internal Medicine Department, Hospital Juan Ramón Jiménez
de Huelva, Huelva, Spain
| |
Collapse
|
33
|
Rodríguez E, Monjo M, Rodríguez-Cuenca S, Pujol E, Amengual B, Roca P, Palou A. Sexual dimorphism in the adrenergic control of rat brown adipose tissue response to overfeeding. Pflugers Arch 2001; 442:396-403. [PMID: 11484771 DOI: 10.1007/s004240100556] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Gender-related differences in the brown adipose tissue (BAT) response to overfeeding rats on a cafeteria diet were studied by assessing the balance between the expression of beta-adrenoceptors (beta1-, beta2-, beta3-AR) and alpha2A-AR and their relation to the expression of uncoupling proteins (UCP1, UCP2, UCP3). Cafeteria diet feeding for 15 days, which involved a similar degree of hyperphagia in both sexes, led to a greater body weight excess in females than in males and a lower activation of thermogenesis. Gender-related differences were found for different adrenoceptor expression and protein levels, which might explain, in part, sex differences in the thermogenic parameters. The lower expression of alpha2A-AR in females than in males could be responsible for the higher expression of UCP1 and thermogenic capacity under non-hyperphagic conditions. However, in a situation of high adrenergic stimulation--as occurs with overfeeding--as there is a preferential recruitment of the beta3-AR by noradrenaline compared with other adrenergic receptors, the higher levels of beta3-AR in males rats than in females could be responsible for the greater thermogenic capacity and the lesser weight gain in males. Thus, the alpha2/beta3 balance in BAT could be a key in the thermogenic control.
Collapse
MESH Headings
- Adipose Tissue, Brown/chemistry
- Adipose Tissue, Brown/physiology
- Animals
- Carrier Proteins/genetics
- Diet
- Eating/physiology
- Female
- Gene Expression/physiology
- Ion Channels
- Male
- Membrane Proteins/genetics
- Membrane Transport Proteins
- Mitochondrial Proteins
- Obesity/genetics
- Obesity/physiopathology
- Proteins/genetics
- RNA, Messenger/analysis
- Rats
- Rats, Wistar
- Receptors, Adrenergic, alpha-2/analysis
- Receptors, Adrenergic, alpha-2/genetics
- Receptors, Adrenergic, beta/analysis
- Receptors, Adrenergic, beta/genetics
- Sex Characteristics
- Uncoupling Protein 1
- Uncoupling Protein 2
- Uncoupling Protein 3
Collapse
Affiliation(s)
- E Rodríguez
- Departament de Biologia Molecular, Nutricó i Biotecnologia, Universitat de les Illes Balears, Palma de Mallorca, Spain
| | | | | | | | | | | | | |
Collapse
|
34
|
Cruz J, Mendez M, Alfonso P, Gonzalez E, Pujol E, Castañon C, Cerezuela P. A phase II study of weekly irinotecan (CPT-11) and oral uracil and ftorafur (UFT) plus folinic acid (FA) as first line treatment in advanced colorectal cancer (CRC). Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81581-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Martínez-García T, Sobrino JM, Pujol E, Galvez J, Benítez E, Girón-González JA. Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus. Heart 2000; 84:620-4. [PMID: 11083740 PMCID: PMC1729508 DOI: 10.1136/heart.84.6.620] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
OBJECTIVE Echocardiographic and Doppler analysis of myocardial mass and diastolic function in patients infected with HIV. DESIGN Case-control study. SETTING Tertiary referral centre, Huelva, Spain. PATIENTS 61 asymptomatic patients with HIV infection and 32 healthy controls. MAIN OUTCOME MEASURES Time motion, cross sectional, and Doppler echocardiographic studies were performed, and left ventricular mass and diastolic function variables determined (peak velocity of early and late mitral outflow and isovolumic relaxation time). RESULTS Left ventricular mass index (LVMI) was decreased in patients compared with healthy controls (mean (SD): 76.7 (23.6) v 118.8 (23.5) g/m(2), p < 0.001). Linear regression analysis showed a correlation between LVMI and brachial fat and muscle areas. The ratio of peak velocities of early and late mitral outflow was decreased in HIV infected patients compared with controls (1.19 (0.44) v 1.58 (0.38), p < 0.001). This ratio was exclusively related to haemodynamic variables (heart rate, systolic and diastolic blood pressures). HIV infected patients had a prolonged isovolumic relaxation time (103.0 (10.5) v 72.9 (12.9) ms, p < 0.001). Isovolumic relaxation time was correlated only with brachial muscle area on multivariate analysis. CONCLUSIONS HIV infected patients had a reduced left ventricular mass index and diastolic functional abnormalities. These cardiac abnormalities are predominantly related to nutritional status.
Collapse
Affiliation(s)
- T Martínez-García
- Department of Internal Medicine, Hospital Juan Ramón Jiménez, Huelva, Spain
| | | | | | | | | | | |
Collapse
|
36
|
Redondo LM, Valerdiz S, Pujol E, Serrat A, Alonso A, Verrier A. Glomus tumour of the palate. Diagnostic and treatment. Med Oral 1999; 4:626-631. [PMID: 11507532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Affiliation(s)
- L.-M. Redondo
- Cirugia Oral y Maxilofacial. Hospital Universitario del Rio Hortega. Valladolid. Spain
| | | | | | | | | | | |
Collapse
|
37
|
Gálvez J, Martín I, Merino D, Pujol E. [Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies]. Med Clin (Barc) 1997; 108:396-7. [PMID: 9139149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
38
|
Benitez M, Boto A, Colchero J, Fernandez-Girón F, Rodriguez P, Paralle M, Pujol E. Haemolytic-uraemic syndrome in a patient infected by HIV. Nephrol Dial Transplant 1997; 12:362-3. [PMID: 9132665 DOI: 10.1093/ndt/12.2.362] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
39
|
Lozano F, Torre-Cisneros J, Bascuñana A, Polo J, Viciana P, García-Ordóñez MA, Hernández-Quero J, Márquez M, Vergara A, Díez F, Pujol E, Torres-Tortosa M, Pasquau J, Hernández-Burruezo JJ, Suárez I. Prospective evaluation of fever of unknown origin in patients infected with the human immunodeficiency virus. Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Eur J Clin Microbiol Infect Dis 1996; 15:705-11. [PMID: 8922569 DOI: 10.1007/bf01691956] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The aim of this study was to determine the frequency and aetiology of fever of unknown origin (FUO) in patients infected with the human immunodeficiency virus (HIV), to assess the value of the tests used in its diagnosis, and to evaluate possible models of diagnosis for the causes found most frequently. One hundred twenty-eight (3.5%) of 3603 hospitalised HIV-positive patients evaluated from October 1992 to December 1993 had FUO, defined by established criteria. Eighty-six percent of patients with FUO had previously progressed to AIDS. The median CD4+ cell count was 46/mm3. A definite diagnosis was made in 96 (75%) of the 128 patients and a possible diagnosis in 24 (18.7%). whilst no diagnosis was made in eight cases (6.2%). Tuberculosis (48.3%), visceral leishmaniasis (16%), and infection by Mycobacterium avium complex (6.9%) were the diseases found most frequently. The most useful diagnostic tests were liver biopsy (68.9%) and bone marrow aspirate/biopsy (39.7%). It is not possible to predict clinically the cases of FUO due to tuberculosis, whilst thrombocytopaenia < 100,000 cells/mm3 alone is useful for differentiating the cases of visceral leishmaniasis, with a negative predictive value of 95.2%.
Collapse
Affiliation(s)
- F Lozano
- Infectious Diseases Section, Hospital Universitario de Valme, Seville, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Saavedra J, Merino D, Vega D, Gálvez J, Pascual L, Pujol E. [Polymicrobial endocarditis in an intravenous drug addict with isolation of Eikenella corrodens]. Enferm Infecc Microbiol Clin 1996; 14:454-6. [PMID: 8991449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
41
|
Soriano V, Gutierrez M, Vallejo A, Aguilera A, Pujol E, Calderon E, Gonzalez-Lahoz J. Epidemiology of HTLV-I infection in Spain. HTLV Spanish Study Group. Int J Epidemiol 1996; 25:443-9. [PMID: 9119572 DOI: 10.1093/ije/25.2.443] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND The human T-lymphotropic virus type I (HTLV-I) has been implicated in the genesis of tropical spastic paraparesis (TSP), adult T-cell lymphoma (ATL), and some cases of uveitis, subacute arthropathies, chronic dermatitis and lymphocytic alveolitis. The virus is endemic in some areas of the Caribbean basin, Japan, subSaharan Africa, Central and South America, Middle East and Melanesia. Given that HTLV-I is transmitted through similar ways to HIV, screening in blood donors is recommended in some countries. MATERIALS AND METHODS The clinical, epidemiological and virological characteristics of 27 patients with HTLV-I infection were identified in Spain up to September 1995. RESULTS Eighteen cases were Spanish natives and 9 were immigrants from endemic areas. Fifteen were male and 12 were female. The majority (12/18; 66.7 percent) of subjects born in Spain had resided in endemic areas or had had sexual partners from these regions. Four patients had TSP, three had ATL and one developed lymphomatous granulomatosis and T-cell lymphoma. The remaining HTLV-I subjects were asymptomatic at the time of diagnosis. Four cases were identified from screening of blood donors. CONCLUSION HTLV-I is present in Spain, affecting natives and, less frequently, immigrants from endemic areas. Both neurological and lymphoproliferative diseases have been recognized in a quarter of patients.
Collapse
Affiliation(s)
- V Soriano
- C/Rafael Calvo 7, 2 Degrees A, 28010 Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
42
|
Soriano V, Gutiérrez M, Vallejo A, Tuset C, Dronda F, Pujol E. [HTLV-II infection in Spain. Analysis of 113 cases identified until November, 1994. Spanish Group for the Study of HTLV/I/II]. Med Clin (Barc) 1995; 105:251-4. [PMID: 7475465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND HTLV-II is a human retrovirus considered to be responsible for the genesis of some lymphoproliferative and neurologic syndromes. The virus is endemic in some Amerindian and African tribes as well amongst injecting drug addicts (IDA) in North America and Europe. METHODS The clinical, epidemiologic and virologic characteristics of the patients with HTLV-II infection identified in Spain up to November 1994 are described. RESULTS One hundred thirteen subjects have been identified with HTLV-II infection in Spain with 4 being African immigrants residing in Madrid and the remaining being IDA from other European countries. Most were males (94/113; 83%). All were IDA except six (5 had acquired the infection by sexual contact and one by blood transfusion). Most of the IDA infected with HTLV-II were coinfected with HIV-1 (93/113; 83%). No patient showed clinical manifestations attributable to HTLV-II infection although one drug addict male coinfected with HIV-1 and HTLV-II developed a non-inflammatory proximal myopathy. CONCLUSIONS Infection by HTLV-II is present in Spain and affects with preference to injecting drug addicts. It has been shown to be of growing incidence with a current global prevalence of 2% in IDA.
Collapse
Affiliation(s)
- V Soriano
- Instituto de Salud Carlos III, Madrid
| | | | | | | | | | | |
Collapse
|
43
|
Henrard DR, Soriano V, Robertson E, Gutierrez M, Stephens J, Dronda F, Miles F, Pujol E, Buytendorp M, Castro A. Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. J Clin Microbiol 1995; 33:1735-8. [PMID: 7665638 PMCID: PMC228259 DOI: 10.1128/jcm.33.7.1735-1738.1995] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection in 1992 and 1993 was determined by testing 2,152 specimens from injection drug users living in 11 geographic areas in Spain. Results obtained by an authentic HTLV-1 and -2 test were compared with those obtained by an HTLV-1 assay. HTLV infection was identified in 7 of 11 regions, with an overall prevalence of 2.5% (range, 0.4 to 11.5%). Fourty-four (81%) of 54 subjects were infected with HTLV-2; the viral strains in the remaining 10 subjects could not be serologically typed. Underestimation of HTLV infection because of the low sensitivities of HTLV-1 enzyme immunoassays for HTLV-2 antibody was relatively low (< 20%). Therefore, previous epidemiologic findings generated with HTLV-1 enzyme immunoassays appear to be reasonably accurate. Our results suggest that the rate of HTLV infection may have been increasing recently among Spanish drug users.
Collapse
|
44
|
Ramos M, Merino D, Domínguez A, Pujol E. [Hepatitis E]. Rev Clin Esp 1995; 195:437-9. [PMID: 7644796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- M Ramos
- Sección de Aparato Digestivo, Hospital General Juan Ramón Jiménez, Huelva
| | | | | | | |
Collapse
|
45
|
Martínez T, Colchero J, Conde J, Creahg R, Pujol E. [Severe gastrointestinal complication of Behcet's disease]. An Med Interna 1995; 12:25-7. [PMID: 7718713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We describe a case of Behçet's syndrome with ileoceal affection of the gastrointestinal track, torpid course evolving to an intermittent febrile syndrome and associated to clinical signs of acute abdomen and latter septic complication due to a fecaloid fistula after surgery. We discuss the similarities with the inflammatory intestinal disease and the problem of the diagnosis and treatment of this particular implication of Behçet's syndrome.
Collapse
Affiliation(s)
- T Martínez
- Servicio de Medicina Interna, Hospital General Juan Ramón Jiménez, Huelva
| | | | | | | | | |
Collapse
|
46
|
León M, Ramos M, Saavedra J, Domínguez A, Ferrer T, Pujol E. [S. pneumoniae sternoclavicular arthritis in a patient with HIV infection]. An Med Interna 1994; 11:395-7. [PMID: 7772688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
HIV infection is a predisposing factor for pneumococcic infection. While pneumonia is the most frequent location, other locations (articular, meningeal, endocardiac, etc) have been less frequently described. Among the articular infections described in patients with HIV infection, the sternoclavicular affection is extremely rare and it usually develops in association with parenterally drug addiction, being Staphylococcus aureus and Pseudomonas aeruginosa the most frequently germs involved. We describe the first case of sternoclavicular arthritis by Streptococcus pneumoniae in a patient with HIV infection. In our case, the chronic hepatopathy associated to alcohol consumption is a predisposing factor related to the pneumococcic infection. Our case suggests the need to formally investigate the HIV infection in young patients with invasive pneumococcic infection.
Collapse
Affiliation(s)
- M León
- Servicio de Medicina Interna, Hospital General de Huelva
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
A case of septic arthritis due to Haemophilus aphrophilus is presented. This organism has rarely been reported as a cause of bone or joint infections. We believe this is the third reported case of septic arthritis caused by this microorganism. We review the clinical and bacteriologic findings and the previously reported cases of infection caused by H. aphrophilus. Treatment with ceftriaxone was followed by full recovery without sequelae.
Collapse
Affiliation(s)
- D Merino
- Servicio de Medicina Interna, Hospital Manuel Lois, Huelva, Spain
| | | | | | | | | | | | | |
Collapse
|
48
|
Rodríguez JN, Aguayo DM, Martín I, Diéguez JC, Prados D, Pujol E. [Hodgkin's disease and HIV: relations between CD4/CD8 rate, histology and stage]. Rev Clin Esp 1994; 194:543-6. [PMID: 7938823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Hodgkin's disease (HD) is not currently accepted as an AIDS diagnostic criterion by the Centers for Disease Control (Atlanta), although there are reports on a higher incidence of the disease in HIV infected patients, with the special feature of a marked clinical and histological aggressiveness. A review of the literature was made and a total of 54 cases of HD compiled of patients with HIV infection. The relationships between the absolute counts of CD4 and the CD4/CD8 ratio with histopathology and with the stage at diagnosis was investigated. No significant differences were found between the absolute counts of CD4 and CD4/CD8 ratio with the clinical stage of disease, histopathologic subgroup or presence of B symptoms in HD. Nevertheless, lower CD4 counts were observed in more advanced clinical stages and in patients with B symptoms; the highest CD4/CD8 ratios were observed in patients with more advanced disease. It is hypothesized that immunological disturbances caused by HIV would lead to more aggressive histological lesions and more advanced stages of HD in HIV-positive patients. Thus, the inclusion of HD as a diagnostic criterion of AIDS would be warranted.
Collapse
Affiliation(s)
- J N Rodríguez
- Servicio de Hematología, Hospital Juan Ramón Jiménez, Huelva
| | | | | | | | | | | |
Collapse
|
49
|
Elosua R, Marrugat J, Molina L, Pons S, Pujol E. Validation of the Minnesota Leisure Time Physical Activity Questionnaire in Spanish men. The MARATHOM Investigators. Am J Epidemiol 1994; 139:1197-209. [PMID: 8209878 DOI: 10.1093/oxfordjournals.aje.a116966] [Citation(s) in RCA: 382] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Questionnaires are frequently used for measuring physical activity. The aim of this study was to validate the Spanish version of the Minnesota Leisure Time Physical Activity Questionnaire (MLTPAQ) in Spanish men. Healthy men (n = 187) aged 20-60 years were recruited. The MLTPAQ was administered to assess the quantity (total activity metabolic index) and quality (heavy, moderate, and light) of physical activity performed in the last year, quarter, month, and week. Fitness was assessed with an exercise test. Spearman's correlation coefficients between the total activity metabolic index and exercise test duration, time to maximal theoretical heart rate, and caloric intake were 0.57, 0.46, and 0.40, respectively. The intraclass correlation coefficients between the total activity metabolic indexes in the last year and in the last quarter, month, and week were 0.62, 0.46, and 0.35, respectively. In multiple linear regression, the heavy, moderate, and light activity metabolic index, age, body mass index, and basal heart rate explained 40% of the variability of time to the maximum theoretical heart rate. The Spanish version of the MLTPAQ is a valid instrument to measure the quantity and quality of physical activity performed in the last year (also in periods shorter than 1 year) by Spanish men aged 20-60 years. Only heavy physical activity is related to cardiorespiratory fitness.
Collapse
Affiliation(s)
- R Elosua
- Departament d'Epidemiologia i Salut Pública, Institut Municipal d'Investigació Mèdica, Barcelona, Spain
| | | | | | | | | |
Collapse
|
50
|
Gálvez J, Pujol E, Vega D, Pascual L, Martínez T. [Osteolytic vertebral lesion in an AIDS patient]. Rev Clin Esp 1994; 194:368-9. [PMID: 8059035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- J Gálvez
- Servicio de Medicina Interna, Hospital General de Huelva
| | | | | | | | | |
Collapse
|